Peringatan Keamanan

Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.

Mivacurium

DB01226

small molecule approved

Deskripsi

Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission.

Struktur Molekul 2D

Berat 1029.2608
Wujud liquid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean elimination half-life ranges from 1.7 to 2.6 minutes in healthy, young adults administered 0.1 to 0.25 mg/kg mivacurium. In 9 patients with end-stage liver disease undergoing liver transplant surgery, plasma clearance was approximately 50% lower than that in 8 control patients with normal hepatic function, while the elimination half-life increased to 4.4 minutes from the 1.8 minute control value.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Extensive and rapid via enzymatic hydrolysis catalyzed by plasma cholinesterase. Biotransformation may be significantly slowed in patients with abnormal or decreased plasma cholinesterase activity, especially individuals with a homozygous atypical cholinesterase gene abnormality.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1214 Data
Buprenorphine Mivacurium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Mivacurium.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Mivacurium.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Mivacurium.
Hydrocodone Mivacurium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mivacurium.
Magnesium sulfate The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Mivacurium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Mivacurium may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Mivacurium.
Mirtazapine Mivacurium may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Mivacurium.
Orphenadrine Mivacurium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Mivacurium may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Mivacurium.
Pramipexole Mivacurium may increase the sedative activities of Pramipexole.
Ropinirole Mivacurium may increase the sedative activities of Ropinirole.
Rotigotine Mivacurium may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Mivacurium.
Sodium oxybate The risk or severity of CNS depression can be increased when Mivacurium is combined with Sodium oxybate.
Suvorexant Mivacurium may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Mivacurium.
Thalidomide Mivacurium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Mivacurium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Capreomycin The therapeutic efficacy of Mivacurium can be increased when used in combination with Capreomycin.
Cyclosporine The therapeutic efficacy of Mivacurium can be increased when used in combination with Cyclosporine.
Doxycycline The therapeutic efficacy of Mivacurium can be increased when used in combination with Doxycycline.
Lymecycline The therapeutic efficacy of Mivacurium can be increased when used in combination with Lymecycline.
Framycetin The therapeutic efficacy of Mivacurium can be increased when used in combination with Framycetin.
Clomocycline The therapeutic efficacy of Mivacurium can be increased when used in combination with Clomocycline.
Quinine The therapeutic efficacy of Mivacurium can be increased when used in combination with Quinine.
Vancomycin The therapeutic efficacy of Mivacurium can be increased when used in combination with Vancomycin.
Tigecycline The therapeutic efficacy of Mivacurium can be increased when used in combination with Tigecycline.
Oxytetracycline The therapeutic efficacy of Mivacurium can be increased when used in combination with Oxytetracycline.
Chloroquine The therapeutic efficacy of Mivacurium can be increased when used in combination with Chloroquine.
Demeclocycline The therapeutic efficacy of Mivacurium can be increased when used in combination with Demeclocycline.
Mecamylamine The therapeutic efficacy of Mivacurium can be increased when used in combination with Mecamylamine.
Tobramycin The therapeutic efficacy of Mivacurium can be increased when used in combination with Tobramycin.
Tetracycline The therapeutic efficacy of Mivacurium can be increased when used in combination with Tetracycline.
Gentamicin The therapeutic efficacy of Mivacurium can be increased when used in combination with Gentamicin.
Etacrynic acid The therapeutic efficacy of Mivacurium can be increased when used in combination with Etacrynic acid.
Quinidine The therapeutic efficacy of Mivacurium can be increased when used in combination with Quinidine.
Metacycline The therapeutic efficacy of Mivacurium can be increased when used in combination with Metacycline.
Netilmicin The therapeutic efficacy of Mivacurium can be increased when used in combination with Netilmicin.
Neomycin The therapeutic efficacy of Mivacurium can be increased when used in combination with Neomycin.
Streptomycin The therapeutic efficacy of Mivacurium can be increased when used in combination with Streptomycin.
Colistimethate The therapeutic efficacy of Mivacurium can be increased when used in combination with Colistimethate.
Kanamycin The therapeutic efficacy of Mivacurium can be increased when used in combination with Kanamycin.
Rolitetracycline The therapeutic efficacy of Mivacurium can be increased when used in combination with Rolitetracycline.
Magnesium oxide The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium oxide.
Magnesium cation The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium cation.
Paromomycin The therapeutic efficacy of Mivacurium can be increased when used in combination with Paromomycin.
Lincomycin The therapeutic efficacy of Mivacurium can be increased when used in combination with Lincomycin.
Ribostamycin The therapeutic efficacy of Mivacurium can be increased when used in combination with Ribostamycin.
Geneticin The therapeutic efficacy of Mivacurium can be increased when used in combination with Geneticin.
Apramycin The therapeutic efficacy of Mivacurium can be increased when used in combination with Apramycin.
Gentamicin C1a The therapeutic efficacy of Mivacurium can be increased when used in combination with Gentamicin C1a.
Neamine The therapeutic efficacy of Mivacurium can be increased when used in combination with Neamine.
Arbekacin The therapeutic efficacy of Mivacurium can be increased when used in combination with Arbekacin.
Viomycin The therapeutic efficacy of Mivacurium can be increased when used in combination with Viomycin.
Puromycin The therapeutic efficacy of Mivacurium can be increased when used in combination with Puromycin.
Magnesium hydroxide The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium hydroxide.
Magnesium trisilicate The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium trisilicate.
Magnesium chloride The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium chloride.
Magnesium acetate tetrahydrate The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium acetate tetrahydrate.
Magnesium carbonate The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium carbonate.
Magnesium citrate The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium citrate.
Magnesium glycinate The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium glycinate.
Magnesium Aluminum Silicate The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium Aluminum Silicate.
Dihydrostreptomycin The therapeutic efficacy of Mivacurium can be increased when used in combination with Dihydrostreptomycin.
Hygromycin B The therapeutic efficacy of Mivacurium can be increased when used in combination with Hygromycin B.
Sisomicin The therapeutic efficacy of Mivacurium can be increased when used in combination with Sisomicin.
Plazomicin The therapeutic efficacy of Mivacurium can be increased when used in combination with Plazomicin.
Magnesium silicate The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium silicate.
Penimepicycline The therapeutic efficacy of Mivacurium can be increased when used in combination with Penimepicycline.
Magnesium aspartate The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium aspartate.
Isepamicin The therapeutic efficacy of Mivacurium can be increased when used in combination with Isepamicin.
Magnesium gluconate The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium gluconate.
Magnesium orotate The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium orotate.
Magnesium phosphate The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium phosphate.
Magnesium acetate The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium acetate.
Procainamide The therapeutic efficacy of Mivacurium can be increased when used in combination with Procainamide.
Dantrolene The therapeutic efficacy of Mivacurium can be increased when used in combination with Dantrolene.
Piperacillin The therapeutic efficacy of Mivacurium can be increased when used in combination with Piperacillin.
Magnesium stearate The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium stearate.
Colistin The therapeutic efficacy of Mivacurium can be increased when used in combination with Colistin.
Aclidinium The risk or severity of adverse effects can be increased when Mivacurium is combined with Aclidinium.
Mianserin Mianserin may increase the anticholinergic activities of Mivacurium.
Mirabegron The risk or severity of urinary retention can be increased when Mivacurium is combined with Mirabegron.
Potassium chloride The risk or severity of gastrointestinal ulceration can be increased when Mivacurium is combined with Potassium chloride.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Mivacurium.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Mivacurium.
Tiotropium The risk or severity of adverse effects can be increased when Mivacurium is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Mivacurium is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Mivacurium is combined with Umeclidinium.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Mivacurium.
Glycopyrronium The risk or severity of adverse effects can be increased when Mivacurium is combined with Glycopyrronium.
Spironolactone Spironolactone may increase the neuromuscular blocking activities of Mivacurium.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Mivacurium is combined with Botulinum toxin type A.
Glucagon Mivacurium may increase the gastrointestinal motility reducing activities of Glucagon.

Target Protein

Neuronal acetylcholine receptor subunit alpha-2 CHRNA2
Muscarinic acetylcholine receptor M2 CHRM2
Muscarinic acetylcholine receptor M3 CHRM3
Cholinesterase BCHE

Referensi & Sumber

Synthesis reference: Maurizio Francesco Velati, Andrea Busca, Cristina Manfrotto, Marco Nicolini, Claudio Gianluca Pozzoli, "Process for the preparation of mivacurium chloride." U.S. Patent US20070293534, issued December 20, 2007.

Contoh Produk & Brand

Produk: 5 • International brands: 0
Produk
  • Mivacron
    Injection, solution • 2 mg/1mL • Intravenous • US • Approved
  • Mivacron
    Injection, solution • 2 mg/1mL • Intravenous • US • Approved
  • Mivacron
    Solution • 2 mg/1mL • Intravenous • US • Approved
  • Mivacron
    Liquid • 2 mg / mL • Intravenous • Canada • Approved
  • Mivacurium Chloride
    Injection, solution • 2 mg/1mL • Intravenous • US

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul